Stig Anders Lindberg

Provides wealth management, securities trading and sales, corporate finance and investment banking services

Provides cell-based screening services to accelerate drug discovery

Develops and markets cardiology devices

Operates as a clinical-stage biotechnology company that develops radioligand therapies for cancer treatment

Operates as a management consulting firm

Provides biopharmaceuticals services

IGC is a long-term investor with a top-down investment approach. They describe their investment attitude as patient and flexible. They are active investment partners seeking management teams operating in markets displaying sustainable growth characteristics. IGC commits themselves to board representation working closely for strategic decisions, financial and human resource allocations, potential acquisitions analyses and sources of additional capital. Their investee firms gain access to IGC's worldwide network of industry experts, advisors, and local knowledge over several geographic markets. IGC Europe invests primarily in expansion-stage firms in the technology and life sciences sectors in Northern Europe. They have an investment horizon from three to seven years. They typically invest between USD $3 million and $30 million. They acquire minority interest. IGC Asia targets expansion-stage firms in IT, software, semiconductors and Internet/media within Asia. Their investments range from USD $8 to $15 million over an investment period of three to six years. IGC US concentrates on investments in unlisted firms in healthcare and either listed or unlisted firms in IT sectors in North America. Generally, they invest in healthcare firms that have approved or marketed products. IT investments will typically be beyond the concept stage.

Functions as a College/University

Operates as a clinical stage biotechnology company that develops antibodies for the treatment of cancers